X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7192) 7192
Book Review (1274) 1274
Publication (545) 545
Book Chapter (26) 26
Conference Proceeding (18) 18
Dissertation (11) 11
Magazine Article (7) 7
Web Resource (6) 6
Trade Publication Article (2) 2
Government Document (1) 1
Newspaper Article (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
bevacizumab (5863) 5863
index medicus (5438) 5438
humans (5006) 5006
ophthalmology (3261) 3261
female (2924) 2924
male (2599) 2599
middle aged (1986) 1986
vascular endothelial growth factor a - antagonists & inhibitors (1976) 1976
aged (1949) 1949
angiogenesis inhibitors - therapeutic use (1902) 1902
antibodies, monoclonal, humanized (1895) 1895
vascular endothelial growth factor (1810) 1810
endothelial growth-factor (1780) 1780
macular degeneration (1544) 1544
ranibizumab (1525) 1525
oncology (1487) 1487
angiogenesis inhibitors - administration & dosage (1486) 1486
treatment outcome (1468) 1468
intravitreal injections (1252) 1252
adult (1158) 1158
avastin (1158) 1158
cancer (1149) 1149
angiogenesis (1109) 1109
antibodies, monoclonal - therapeutic use (1019) 1019
aged, 80 and over (1008) 1008
retrospective studies (1005) 1005
care and treatment (971) 971
animals (945) 945
antibodies, monoclonal - administration & dosage (919) 919
tomography, optical coherence (911) 911
eye diseases (890) 890
chemotherapy (869) 869
angiogenesis inhibitors (832) 832
medicine & public health (819) 819
therapy (816) 816
fluorescein angiography (806) 806
follow-up studies (777) 777
neovascularization (727) 727
vegf (726) 726
antibodies, monoclonal, humanized - therapeutic use (722) 722
angiogenesis inhibitors - adverse effects (719) 719
genetic structures (713) 713
intravitreal bevacizumab (710) 710
drug therapy (704) 704
injections (704) 704
research (693) 693
antibodies, monoclonal, humanized - administration & dosage (692) 692
injection (688) 688
visual acuity (685) 685
visual acuity - physiology (653) 653
diabetic retinopathy (623) 623
vitreous body (610) 610
photodynamic therapy (607) 607
choroidal neovascularization - drug therapy (591) 591
sense organs (575) 575
prospective studies (562) 562
choroidal neovascularization (561) 561
macular degeneration - drug therapy (545) 545
pharmacology & pharmacy (543) 543
analysis (537) 537
antineoplastic combined chemotherapy protocols - therapeutic use (528) 528
surgery (527) 527
macular edema - drug therapy (495) 495
retina (494) 494
antibodies, monoclonal - adverse effects (487) 487
metastasis (455) 455
patients (430) 430
clinical trials (427) 427
macular edema (425) 425
edema (423) 423
age-related macular degeneration (411) 411
health aspects (409) 409
studies (395) 395
intravitreal injection (393) 393
angiogenesis inhibitors - pharmacology (386) 386
safety (385) 385
physiological aspects (381) 381
vascular endothelial growth factor a - metabolism (381) 381
retinopathy (379) 379
tumors (376) 376
mice (375) 375
optical coherence tomography (375) 375
bevacizumab - administration & dosage (371) 371
trial (367) 367
antineoplastic agents (360) 360
colorectal cancer (360) 360
bevacizumab avastin (358) 358
antimitotic agents (352) 352
abridged index medicus (344) 344
verteporfin (344) 344
diabetic retinopathy - drug therapy (343) 343
expression (339) 339
antibodies, monoclonal, humanized - adverse effects (331) 331
diabetes (331) 331
intravitreal bevacizumab avastin (325) 325
risk factors (325) 325
bevacizumab - therapeutic use (321) 321
antineoplastic agents - therapeutic use (319) 319
efficacy (319) 319
combined modality therapy (314) 314
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6756) 6756
German (152) 152
Korean (120) 120
French (75) 75
Spanish (41) 41
Chinese (16) 16
Portuguese (13) 13
Russian (11) 11
Japanese (9) 9
Turkish (9) 9
Polish (8) 8
Czech (7) 7
Romanian (6) 6
Italian (3) 3
Hebrew (2) 2
Hungarian (2) 2
Slovak (2) 2
Slovenian (2) 2
Croatian (1) 1
Dutch (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Oncologist, ISSN 1083-7159, 06/2007, Volume 12, Issue 6, pp. 713 - 718
Journal Article
OPHTHALMOLOGY, ISSN 0161-6420, 05/2007, Volume 114, Issue 5, pp. 855 - 859
Purpose: To describe the pharmacokinetics of 1.25 mg of intravitreal bevacizumab (Avastin). Design: Experimental animal study. Participants: Twenty... 
REGRESSION | CLEARANCE | PROLIFERATIVE DIABETIC-RETINOPATHY | INJECTION | COHERENCE TOMOGRAPHY FINDINGS | OPHTHALMOLOGY | MACULAR DEGENERATION | RETINAL VEIN OCCLUSION | BEVACIZUMAB AVASTIN | NEOVASCULARIZATION | SHORT-TERM
Journal Article
Indian Journal of Ophthalmology, ISSN 0301-4738, 07/2017, Volume 65, Issue 7, pp. 545 - 548
[...]anti-VEGF agents are often the first-line drugs which have shown to improve visual acuity, rather than just prevent vision loss. [2] Although the... 
OPHTHALMOLOGY | ENDOPHTHALMITIS | INJECTION | ENDOTHELIAL GROWTH-FACTOR | Macular degeneration | Vascular endothelial growth factor | Research | Antibiotics | Surgeons | Retina | Nosocomial infections | Ophthalmology | Patients | Iodine | Bevacizumab | Index Medicus
Journal Article
BMC CANCER, ISSN 1471-2407, 05/2019, Volume 19, Issue 1, pp. 433 - 433
Journal Article
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 387, Issue 10026, pp. 1405 - 1414
Journal Article
Journal Article
Graefe's Archive for Clinical and Experimental Ophthalmology, ISSN 0721-832X, 1/2008, Volume 246, Issue 1, pp. 81 - 87
Vascular endothelial growth factor (VEGF) plays an important role in many diseases of the posterior pole that are characterized by macular edema and/or... 
Angiogenesis | Intravitreal bevacizumab | Medicine & Public Health | Choroidal neovascularization | Age-related macular degeneration | Proliferative diabetic retinopathy | Diabetic macular edema | Ophthalmology | Safety | intravitreal bevacizumab | PHOTODYNAMIC THERAPY | choroidal neovascularization | angiogenesis | COHERENCE TOMOGRAPHY FINDINGS | BARRIER | MACULAR DEGENERATION | VERTEPORFIN | PHARMACOKINETICS | safety | PEGAPTANIB | GROWTH-FACTOR APTAMER | OPHTHALMOLOGY | age-related macular degeneration | proliferative diabetic retinopathy | diabetic macular edema | SUBFOVEAL CHOROIDAL NEOVASCULARIZATION | BREAKDOWN | Diabetic Retinopathy - drug therapy | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Macular Degeneration - drug therapy | Bevacizumab | Diabetic Retinopathy - physiopathology | Antibodies, Monoclonal, Humanized | Choroidal Neovascularization - drug therapy | Time Factors | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Vitreous Body | Adult | Female | Retrospective Studies | Angiogenesis Inhibitors - adverse effects | Retinal Vein Occlusion - physiopathology | Macular Degeneration - physiopathology | Treatment Outcome | Visual Acuity | Choroidal Neovascularization - physiopathology | Retreatment | Injections | Retinal Vein Occlusion - drug therapy | Macular Edema - physiopathology | Macular Edema - drug therapy | Aged | Endothelial growth factors | Safety and security measures | Angiogenesis inhibitors | Index Medicus
Journal Article
Ophthalmology, ISSN 0161-6420, 2007, Volume 114, Issue 5, pp. 855 - 859
Journal Article